Maury Raycroft
Stock Analyst at Jefferies
(0.42)
# 3,911
Out of 4,818 analysts
54
Total ratings
17.07%
Success rate
-24.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $7.34 | +622.07% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $2.07 | +286.47% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.76 | +294.68% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $2.57 | +172.90% | 1 | Dec 6, 2024 | |
| ERAS Erasca | Initiates: Buy | $6 | $1.43 | +319.58% | 1 | Nov 18, 2024 | |
| INZY Inozyme Pharma | Assumes: Buy | $16 → $17 | $0.98 | +1,631.69% | 1 | Aug 13, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $1.49 | +1,175.17% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $1.78 | +742.70% | 1 | May 7, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $21.75 | +79.31% | 2 | Mar 22, 2024 | |
| CUE Cue Biopharma | Initiates: Buy | $6 | $0.83 | +627.27% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.77 | +1,199.44% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $7.89 | +2,371.48% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $7.96 | +38.19% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $6 → $9 | $0.33 | +2,663.28% | 2 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $22.47 | -73.30% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $13.05 | +474.71% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $218 → $232 | $242.16 | -4.20% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $3.97 | +177.08% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $10.02 | +169.46% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.50 | +233.33% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $11.12 | +331.65% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $6.95 | +417.99% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $3.56 | +2,849.44% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $38.60 | +345.60% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $1.60 | +2,837.50% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 → $40 | $0.77 | +5,124.66% | 5 | Aug 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $4.58 | +4,921.83% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $8.10 | +418.52% | 3 | Nov 1, 2017 |
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $7.34
Upside: +622.07%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $2.07
Upside: +286.47%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.76
Upside: +294.68%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $2.57
Upside: +172.90%
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $1.43
Upside: +319.58%
Inozyme Pharma
Aug 13, 2024
Assumes: Buy
Price Target: $16 → $17
Current: $0.98
Upside: +1,631.69%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $1.49
Upside: +1,175.17%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $1.78
Upside: +742.70%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $21.75
Upside: +79.31%
Cue Biopharma
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.83
Upside: +627.27%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.77
Upside: +1,199.44%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $7.89
Upside: +2,371.48%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $7.96
Upside: +38.19%
May 12, 2023
Upgrades: Buy
Price Target: $6 → $9
Current: $0.33
Upside: +2,663.28%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $22.47
Upside: -73.30%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $13.05
Upside: +474.71%
Oct 3, 2022
Maintains: Buy
Price Target: $218 → $232
Current: $242.16
Upside: -4.20%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $3.97
Upside: +177.08%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $10.02
Upside: +169.46%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.50
Upside: +233.33%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $11.12
Upside: +331.65%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $6.95
Upside: +417.99%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $3.56
Upside: +2,849.44%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $38.60
Upside: +345.60%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $1.60
Upside: +2,837.50%
Aug 28, 2018
Upgrades: Buy
Price Target: $18 → $40
Current: $0.77
Upside: +5,124.66%
Jul 16, 2018
Initiates: Buy
Price Target: $230
Current: $4.58
Upside: +4,921.83%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $8.10
Upside: +418.52%